Infant formula milk powder with function of preventing obesity and preparation method of infant formula milk powder

Abstract

The invention discloses infant formula milk powder with an effect of preventing obesity and a preparation method of the infant formula milk powder. Relates to the technical field of dairy products. Comprising the following steps: preparing MFGM / MPL into a solution by using PBS (Phosphate Buffer Solution), and magnetically stirring into a water phase; compound vegetable oil is used as an oil phase; mixing the oil phase and the water phase, shearing, filtering, and homogenizing at high pressure to obtain an MFGM / MPL emulsion; uniformly mixing the milk base material in water; mixing the MFGM / MPL emulsion with the mixed milk base material, and performing high-pressure homogenization to obtain uniformly mixed infant blending powder material liquid; and sterilizing, concentrating, spray-drying and airing powder to obtain the infant blending powder material. And uniformly mixing the infant blending powder materials, the compound vitamins and the compound minerals, and packaging. The surfaces of fat globules of the prepared infant blending powder are wrapped by MFGM / MPL, digestion and absorption of infants are better facilitated, the wrapping rate is high, and stability is good. The beverage has the efficacy of preventing obesity and related metabolic diseases, and nutrients are retained to a great extent by adopting a dry-wet method composite process.

Description

Technical Field

[0001] The invention relates to the technical field of dairy products, and more particularly to an infant formula milk powder with the function of preventing obesity and a preparation method thereof. Background Art

[0002] At present, intervention measures for childhood overweight and obesity mainly focus on dietary intervention, exercise intervention, behavioral intervention and psychological intervention. Among them, breastfeeding is an important protective measure to prevent childhood obesity. Compared with non-breastfed children, breastfed children have a 15% lower risk of overweight in childhood. The obesity detection rate of children who are artificially fed during infancy is significantly higher than that of breastfed children.

[0003] One of the main reasons for the metabolic differences between breast-fed infants and infant formula-fed infants is that breast milk and infant formula have significant differences in composition and structure. The core of breast milk fat globules is triglyceride, and the surface is covered by milk fat globule membrane (MFGM). The surface of fat globules in infant formula is mainly covered by protein membrane formed during the production and processing process, and the main components are whey protein and casein. MFGM is a three-layer structure composed of polar lipids and proteins, consisting of phospholipids, glycosphingolipids and membrane-specific proteins (mainly glycoproteins). MFGM and its key component milk fat globule membrane phospholipids (MPL) have been shown in animals and clinical trials to have important effects on infant brain development, intestinal health and metabolism. At the same time, MPL has been shown to reduce liver steatosis and chronic inflammation associated with dietary obesity in mice, effectively reduce liver lipid levels in obese / diabetic mice, and induce browning of white fat (WAT) by regulating the expression of Ucp1. Therefore, MFGM and its key component MPL have a significant effect on human fat accumulation and lipid metabolism.

[0004] However, although MFGM or its key components have been added to the existing commercial infant formula, due to the damage during processing, the fat globule interface is mostly milk protein, and only a few phospholipids are wrapped on the surface of the fat globules, while most of the phospholipids are still in the water phase.

[0005] Therefore, how to simulate breast milk fat in terms of fat globule composition and structure and provide an infant formula milk powder with the effect of preventing obesity and a preparation method thereof are problems that technicians in this field urgently need to solve. Summary of the invention

[0006] In view of this, the present invention provides an infant formula milk powder with obesity prevention effect and a preparation method thereof.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] A method for preparing infant formula milk powder having an obesity prevention effect comprises the following steps:

[0009] S1: MFGM / MPL was prepared into a solution with PBS and magnetically stirred overnight to make it evenly dispersed to form the aqueous phase;

[0010] S2: Using composite vegetable oil as the oil phase; mixing the oil phase and the water phase, filtering after shearing, and high-pressure homogenizing to obtain MFGM / MPL emulsion;

[0011] S3: mixing the milk-based materials including skimmed milk powder, desalted whey powder, lactose, calcium chloride and taurine in water;

[0012] S4: Mix the MFGM / MPL emulsion and the milk base material obtained by mixing S3, and homogenize under high pressure to obtain a mixed infant formula powder liquid;

[0013] S5: sterilizing, concentrating, spray drying, and air drying the infant formula powder liquid to obtain an infant formula powder material;

[0014] S6: Evenly mix the infant formula powder material, the multivitamins and the multiminerals, and package them to obtain an infant formula milk powder with the function of preventing obesity.

[0015] Preferably, the concentration of PBS in S1 is 5 mM, the magnetic stirring speed is 900 rpm, the stirring temperature is 45° C., the stirring time is 12 h, and the concentration of the MFGM / MPL aqueous solution is 2%.

[0016] Preferably, the mixing ratio of the oil phase and the water phase in S2 is 1:9, the shearing speed of the high-speed homogenizing shearing machine is 10000r / min, the shearing time is 5min, the homogenizing pressure is 15-25MPa, and the average number of times is 2-3 times.

[0017] Preferably, the mixing temperature of S3 is 40-60°C and the mixing time is 30-45 minutes.

[0018] Preferably: the pressure of S4 homogenization is 15-25 MPa, and the average number of times is 2-3 times.

[0019] Preferably: the sterilization temperature in S5 is 135-140°C and the time is 3-5s;

[0020] The spray drying air inlet temperature is 160°C and the air outlet temperature is 75-80°C;

[0021] Concentrating is vacuum concentrating to 23-27% of the volume of the mixed liquid, and controlling the solid mass fraction in the milk to be 30-40%;

[0022] Drying the powder is to quickly cool down the finished milk powder.

[0023] The present invention also provides infant formula milk powder with obesity prevention effect prepared by any of the above preparation methods.

[0024] Preferably, every 100 parts of formula milk powder contains: 17.72 parts of skimmed milk powder, 5.83 parts of desalted whey powder, 47.85 parts of lactose, 4.2 parts of MFGM / MPL, 23.88 parts of compound vegetable oil, 0.15 parts of compound vitamins, 0.2 parts of compound minerals, 0.15 parts of calcium chloride, and 0.02 parts of taurine.

[0025] Preferred: The mass ratio of each component of the complex vitamin is: Vitamin A 0.0005: Vitamin D 0.00009: Vitamin E 0.015: Vitamin C 0.13251: Vitamin B6 0.0016: Folic acid 0.0003;

[0026] The mass ratio of each component of the composite mineral is: ferrous sulfate 0.013: zinc sulfate 0.005: magnesium sulfate 0.000022: calcium carbonate 0.181978;

[0027] The mass proportion of each component of the composite vegetable oil is: rapeseed oil 10%, sunflower oil 10%, soybean oil 15%, coconut oil 25%, palm oil 25%, and corn oil 15%.

[0028] The present invention also provides the use of any of the above-mentioned infant formula milk powders with obesity prevention effects in preparing food.

[0029] It can be seen from the above technical solutions that, compared with the prior art, the present invention discloses an infant formula milk powder with the effect of preventing obesity and a preparation method thereof, and the technical effects achieved are:

[0030] Firstly, the infant formula powder for preventing obesity provided by the present invention supplements the phospholipids lacking in the production and processing process by adding MFGM / MPL, wraps the compound oil with MFGM / MPL, and then introduces other milk-based materials. Compared with the production of traditional milk powder, the surface of the fat globules in the prepared infant formula powder is wrapped with MFGM / MPL, the fat droplet structure is close to that of breast milk, which is more conducive to the digestion and absorption of infants, has a higher wrapping rate and better stability.

[0031] Secondly, the addition of MFGM / MPL has an important impact on the infant's brain development, intestinal health and metabolism. It has the effect of preventing obesity and related metabolic diseases, and has a significant effect on the accumulation of fat and lipid metabolism in the later stage of infant growth.

[0032] Finally, the dry-wet composite process is adopted in the preparation of the infant formula of the present invention, which retains the types and contents of nutrients such as added complex vitamins and complex minerals in the terminal milk powder to a great extent, and can meet the nutritional needs of infant growth to the greatest extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0034] Figure 1 The accompanying drawing is a diagram showing the fat globule structure of the infant formula provided by the present invention.

[0035] Figure 2 The attached figure is a HE staining diagram of liver adipose tissue provided by the present invention.

[0036] Figure 3 The attached figure is a graph showing the expression levels of liver fat lipid synthesis genes provided by the present invention.

[0037] Figure 4 The attached figure is a graph showing the expression level of liver fat lipid oxidation genes provided by the present invention.

[0038] Figure 5 The accompanying drawing is a HE staining diagram of brown adipose tissue provided by the present invention.

[0039] Figure 6 The attached figure is a diagram showing the expression level of brown fat thermogenic genes provided by the present invention.

[0040] Figure 7 The accompanying drawing is a HE staining diagram of white adipose tissue provided by the present invention.

[0041] Figure 8 The attached figure is a diagram showing the expression level of white fat lipid synthesis genes provided by the present invention.

[0042] Fig. 9 The attached figure is a diagram showing the expression level of white fat lipid oxidation genes provided by the present invention.

[0043] Fig.10 The attached figure is a diagram showing the expression levels of white fat browning marker genes provided by the present invention. DETAILED DESCRIPTION

[0044] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0045] The embodiment of the invention discloses an infant formula milk powder with the function of preventing obesity and a preparation method thereof.

[0046] The experimental methods in the examples are conventional methods unless otherwise specified, and the raw materials, reagents and materials used in the following examples are commercially available products unless otherwise specified.

[0047] Example 1

[0048] A method for preparing infant formula milk powder having an obesity prevention effect comprises the following steps:

[0049] S1: MFGM / MPL was prepared into a solution with PBS and magnetically stirred overnight to make it evenly dispersed to form the aqueous phase of (MFGM / MPL emulsion);

[0050] S2: Using compound vegetable oil as the oil phase (MFGM / MPL emulsion); mixing the oil phase and the water phase, shearing with a high-speed shearing homogenizer, passing through a 60-mesh filter, and high-pressure homogenization to obtain MFGM / MPL emulsion (MFGM / MPL emulsion represents compound oils and fats wrapped by milk fat globule membrane / milk fat globule membrane phospholipids);

[0051] S3: Mix the milk-based materials including skimmed milk powder, desalted whey powder, lactose, calcium chloride and taurine in water;

[0052] S4: Mix the MFGM / MPL emulsion and the milk base material obtained by mixing S3, and homogenize under high pressure to obtain a mixed infant formula powder liquid;

[0053] S5: sterilizing, concentrating, spray drying and air drying the infant formula powder liquid to obtain the infant formula powder material.

[0054] S6: Evenly mix the infant formula powder material, the multivitamins and the multiminerals, and package them to obtain an infant formula milk powder with the function of preventing obesity.

[0055] As a further preferred embodiment, the PBS concentration in S1 is 5 mM, the magnetic stirring speed is 900 rpm, the stirring temperature is 45° C., the stirring time is 12 h, and the concentration of the MFGM / MPL aqueous solution is 2% (w / v).

[0056] As a further preferred embodiment, the mixing ratio of the oil phase and the water phase in S2 is 1:9, the shear speed of the high-speed homogenizer shearing machine is 10000r / min, the shear time is 5min; the homogenization pressure is 20MPa, and the average number of times is 2 times.

[0057] As a further preferred embodiment, the mixing temperature in S3 is 50° C. and the mixing time is 40 min.

[0058] As a further preferred embodiment, the homogenization pressure of S4 is 20 MPa, and the average number of times is 2 times.

[0059] As a further preferred embodiment, the sterilization temperature in S5 is 138° C. and the time is 4 s.

[0060] The spray drying air inlet temperature is 160℃ and the air outlet temperature is 78℃.

[0061] Concentration is vacuum concentration to 25% of the volume of the mixed liquid, and the solid mass fraction in the milk is controlled at 35%;

[0062] Drying the powder means quickly cooling the finished milk powder to room temperature (25°C).

[0063] The infant formula milk powder with the effect of preventing obesity prepared by the above method contains, by weight, 17.72g of skimmed milk powder, 5.83g of desalted whey powder, 47.85g of lactose, 4.2g of MFGM / MPL (milk fat globule membrane / milk fat globule membrane phospholipids), 23.88g of compound vegetable oil, 0.15g of compound vitamins, 0.2g of compound minerals, 0.15g of calcium chloride and 0.02g of taurine per 100g of formula milk powder.

[0064] As a further preferred embodiment, the vitamin complex comprises vitamin A: 0.0005 g; vitamin D: 0.00009 g; vitamin E: 0.015 g; vitamin C: 0.13251 g; vitamin B6: 0.0016 g; and folic acid: 0.0003 g.

[0065] The complex minerals are ferrous sulfate: 0.013g; zinc sulfate: 0.005g; magnesium sulfate: 0.000022g; calcium carbonate: 0.181978g.

[0066] The composite vegetable oils are rapeseed oil (10% w / w, the same below), sunflower oil (10%), soybean oil (15%), coconut oil (25%), palm oil (25%), and corn oil (15%).

[0067] Example 2

[0068] The difference from Example 1 is only in some process parameters:

[0069] S1 magnetic stirring speed is 750rmp;

[0070] The homogenization pressure of S2 is 15MPa, and the average number is 2 times;

[0071] The mixing temperature of S3 is 40℃ and the mixing time is 30min

[0072] The pressure of S4 homogenization is 15MPa, and the average number is 2 times

[0073] The sterilization temperature in S5 is 135°C and the time is 3s

[0074] The spray drying air inlet temperature is 160℃ and the air outlet temperature is 75℃

[0075] The concentration is vacuum concentration to 23% of the volume of the mixed liquid, and the solid mass fraction in the milk is controlled at 30%.

[0076] Example 3

[0077] The difference from Example 1 is only in some process parameters:

[0078] S1 magnetic stirring speed is 1000rmp;

[0079] The homogenization pressure of S2 is 25MPa, and the average number is 3 times;

[0080] The mixing temperature of S3 is 60℃ and the mixing time is 45min.

[0081] The S4 homogenization pressure is 25MPa and the average number of times is 3 times

[0082] The sterilization temperature in S5 is 140℃ and the time is 5s

[0083] The spray drying air inlet temperature is 160℃ and the air outlet temperature is 80℃

[0084] The concentration is vacuum concentration to 27% of the volume of the mixed liquid, and the solid mass fraction in the milk is controlled at 40%.

[0085] (Example 1) Technical effect verification:

[0086] Observation of phospholipid coating on the surface of milk fat globules using ultra-high resolution microscopy

[0087] Gently mix 1 mL of the emulsion with 5 mL of Milli-Q water. Use 1 mg / mL Rd-DOPE, 1 mg / mL FCF, and 42 ug / mL Nile Red to label the phospholipids, proteins, and neutral lipids in the fat globule interface, respectively. Mix 25 μL of Rd DOPE and 100 μL FCF with 200 μL of sample, and mix 100 μL of NR and 250 μL FCF with 500 μL of sample. Store the mixed sample in the dark at room temperature for 1 hour. Take 8 μL of the labeled sample onto a glass slide, cover it with a coverslip, and apply nail polish on the edge of the coverslip to fix the sample position and prevent the sample from drying. The milk fat globule membrane emulsion was observed at 25°C using an ultra-high resolution microscope. The ultra-high resolution microscope is as follows: Figure 1 shown.

[0088] The results showed that: judging from the results of ultra-high resolution microscopy, the addition of MFGM / MPL can effectively improve the impact of the production and processing of infant formula on the surface structure of fat globules. The two milk powders formed fat globules of uniform size, and the surface structure of the fat globules was similar to that of breast milk.

[0089] The effects of early intake of infant formula with MFGM / MPL on later obesity were clarified by measuring the liver adipocyte morphology and mRNA expression of liver lipid oxidation / synthesis genes in mice fed a high-fat diet.

[0090] Male C57BL / 6j mice weaned at postnatal day (PN) 21 were housed at 21±2°C and 50±5% humidity, with a 12-h light / dark cycle, and free access to food and water. The body weight of mice was measured once a week on PN days 21-63. After 7 days of adaptive feeding, the animals were randomly divided into 2 groups at PN24, with n=8 in each group, and were fed their respective diets on PN24-42 days and Western diet (35% w / w fat) on PN42-63 days. To clarify the effect of WSD challenge during puberty, two control groups were included, including a basal control group (CD) group and a high-fat diet control group (HFD), with n=8. The basal control group was fed with AIN93G diet from PN24 to PN42 and AIN93M diet from PN42-63, and the high-fat diet control group was fed with AIN93G diet from P24-42 days and Western diet (WSD) from P42-63 days. The mouse feed was processed and provided in the form of dough. The two infant formula powders were added at 28.3% w / w. The difference in fat between the two infant formula powders was compensated by slightly adjusting the mixed vegetable oil content in the two infant formula powders. The fat part of the infant formula powder feed came entirely from the infant formula powder. The experimental group was divided into MFGM / MPL group according to the addition of different infant formula powders. The Western diet contained 35%, w / w fat (3%, w / w soybean oil; 31.6%, w / w lard and 0.4%, w / w cholesterol).

[0091] Liver histomorphology

[0092] The mouse liver tissue fixed with 4% paraformaldehyde was dehydrated, soaked in soft wax and hard wax, embedded, sliced ​​(5 mm), spread, printed, baked, dewaxed, and stained with hematoxylin-eosin. The slices were placed under an optical microscope to observe the liver tissue morphology. The results of liver tissue HE staining are shown in Figure 2. Figure 2 As shown,

[0093] The results showed that there was no significant difference in the liver tissue morphology between the mice fed with MFGM / MPL and the basic control group, but compared with the mice fed with a high-fat diet, the liver tissue cells of the mice fed with a high-fat diet were deformed, and a large number of fat cells were mixed in the liver cells, and the size was larger, indicating that early intake of infant formula containing MFGM / MPL has the ability to protect mice from liver tissue damage caused by high-fat diet in the later stages of growth.

[0094] mRNA expression of liver lipid oxidation / synthesis genes

[0095] qRT-PCR was used to detect the expression of fatty acid synthase (Fas), sterol regulatory element binding protein-1c (Srebp-1c), stearoyl-CoA desaturase 1 (Scd1), peroxisome proliferator receptor-α (PPARα), carnitine palmitoyltransferase 1α (Cpt-1α), and medium-chain acyl-CoA dehydrogenase (Mcad) in the liver. Total RNA was extracted from liver tissue using AG RNAex Pro Reagent (AGbio, Hunan, China), and its content and purity were determined using an ultramicro spectrophotometer. RNA was reverse transcribed into cDNA according to the instructions of the UniAll-in-One-First-Strand cDNA Synthesis SuperMix for qPCRkit. Subsequently, the reaction system was configured according to the instructions of the Green qPCR SuperMix kit and amplified on a fluorescent quantitative PCR instrument (Bio-Rad, Singapore). β-Actin was used as the internal reference gene for PCR amplification of the target gene, and the final target gene expression was calculated using 2-ΔΔCt. The results are shown in Figure 2. Figure 3-4 shown.

[0096] The results showed that compared with the basic control group, the expression of liver lipid synthesis genes in mice fed a high-fat diet was significantly increased, and the expression of liver lipid oxidation genes was significantly decreased; compared with the mice fed an infant formula supplemented with MFGM / MPL, the expression of liver lipid synthesis genes in the mice fed an infant formula supplemented with MFGM / MPL was significantly reduced, and the expression of liver lipid oxidation genes was significantly increased. The occurrence of liver lipid degeneration and obesity is largely related to the enhanced fat synthesis in liver tissue and the weakened oxidative decomposition. This suggests that early intake of infant formula containing MFGM / MPL can effectively inhibit the occurrence of high-fat diet-induced obesity in mice, thereby preventing the occurrence of obesity in mice in the later stage.

[0097] The morphology of brown adipocytes and the mRNA expression of genes related to brown adipocyte lipid metabolism in mice fed a high-fat diet were measured to clarify the effect of early intake of infant formula with MFGM / MPL on later obesity. The mice were grouped and raised in the same way as above.

[0098] The method for determining brown adipose tissue morphology was the same as above.

[0099] Brown adipose tissue morphology Figure 5 shown.

[0100] The results showed that compared with the basic control group, the high-fat diet caused a certain degree of damage to the brown fat morphology of mice, resulting in an increase in the diameter of mouse adipocytes. Compared with HFD, the intake of infant formula with MFGM / MPL can reduce the damage of high-fat diet to the adipocyte morphology of mice, and there is no significant difference compared with the basic control group.

[0101] Brown fat lipid metabolism gene mRNA expression

[0102] The determination method is the same as above.

[0103] Brown fat metabolic gene expression Figure 6 shown.

[0104] The results showed that compared with the basic control group, the expression of brown fat lipid thermogenic genes in mice fed a high-fat diet was significantly reduced; the expression of brown fat thermogenic genes in mice fed infant formula supplemented with MFGM / MPL was significantly increased compared with mice in the high-fat diet group, indicating that early intake of infant formula containing MFGM / MPL can inhibit the occurrence of high-fat diet-induced obesity in mice by increasing the expression of brown fat thermogenic genes in mice fed a high-fat diet.

[0105] The morphology of white fat, the mRNA expression of genes related to lipid oxidation / synthesis in white fat, and the mRNA expression of genes related to browning of white fat were measured in mice fed a high-fat diet to clarify the effect of early intake of infant formula with MFGM / MPL on later obesity. The mice were grouped and raised in the same way as above.

[0106] White adipose tissue morphology

[0107] The determination method is the same as above.

[0108] The results showed that the morphology of white adipose tissue is Figure 7 As shown, compared with the basic control group, the high-fat diet caused a certain degree of damage to the brown fat morphology of mice, resulting in an increase in the diameter of the mouse fat cells and a large difference in shape. Compared with HFD, the intake of infant formula supplemented with MFGM / MPL can reduce the damage of the high-fat diet to the morphology of mouse fat white cells, and there is no significant difference compared with the basic control group.

[0109] White fat lipid oxidation / synthesis gene mRNA expression

[0110] The determination method is the same as above.

[0111] The results showed that white fat metabolic gene expression Figure 8-9As shown, compared with the basal control group, the expression of lipid oxidation genes in white fat of mice fed a high-fat diet was significantly decreased, while the expression of lipid synthesis genes was significantly increased; compared with the mice fed an infant formula supplemented with MFGM / MPL, the expression of white fat oxidation genes was significantly increased, while the expression of lipid synthesis genes was significantly decreased in mice fed an infant formula supplemented with MFGM / MPL, indicating that early intake of infant formula containing MFGM / MPL can inhibit the occurrence of obesity induced by a high-fat diet in mice by affecting the expression of white fat metabolism genes in mice fed a high-fat diet.

[0112] mRNA expression of marker genes for browning of white fat

[0113] The determination method is the same as above.

[0114] The results showed that the expression of marker genes for browning of white fat Fig.10 As shown. Compared with the basic control group, the expression of white fat browning genes in mice fed a high-fat diet was significantly reduced; the expression of white fat browning genes in mice fed infant formula with MFGM / MPL was significantly increased compared with the high-fat diet group. Enhancing the browning function of adipose tissue can significantly increase the body's energy consumption and play an important role in the body's metabolic health. Therefore, early intake of infant formula containing MFGM / MPL can improve the metabolic function of mice induced by a high-fat diet by affecting the expression of white fat metabolic genes in mice fed a high-fat diet and inhibit the occurrence of obesity.

[0115] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0116] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for preparing infant formula milk powder having an obesity prevention effect, characterized in that: The following steps are involved: S1: MFGM / MPL was prepared into a solution with PBS and magnetically stirred overnight to make it evenly dispersed to form the aqueous phase; S2: composite vegetable oil as the oil phase; The oil phase and the water phase are mixed, filtered after shearing, and homogenized under high pressure to obtain the MFGM / MPL emulsion; S3: mixing the milk-based materials including skimmed milk powder, desalted whey powder, lactose, calcium chloride and taurine in water; S4: Mix the MFGM / MPL emulsion and the milk base material obtained by mixing S3, and homogenize under high pressure to obtain a mixed infant formula powder liquid; S5: sterilizing, concentrating, spray drying, and air drying the infant formula powder liquid to obtain an infant formula powder material; S6: Evenly mix the infant formula powder material, the multivitamins and the multiminerals, and package them to obtain an infant formula milk powder with the function of preventing obesity.

2. The preparation method according to claim 1, characterized in that The PBS concentration in S1 is 5 mM, the magnetic stirring speed is 900 rpm, the stirring temperature is 45° C., the stirring time is 12 h, and the concentration of the MFGM / MPL aqueous solution is 2%.

3. The preparation method according to claim 2, characterized in that: The mixing ratio of the oil phase and the water phase in S2 is 1:9, the shear speed of the high-speed homogenizer shearing machine is 10000r / min, and the shearing time is 5min; the homogenization pressure is 15-25MPa, and the average number of times is 2-3 times.

4. The preparation method according to claim 3, characterized in that: The mixing temperature in S3 is 40-60° C. and the mixing time is 30-45 min.

5. The preparation method according to claim 4, characterized in that: The homogenization pressure in S4 is 15 to 25 MPa, and the average number of times is 2 to 3 times.

6. The preparation method according to claim 5, characterized in that: The sterilization temperature in S5 is 135-140°C and the time is 3-5s; The spray drying air inlet temperature is 160°C and the air outlet temperature is 75-80°C; Concentrating is vacuum concentrating to 23-27% of the volume of the mixed liquid, and controlling the solid mass fraction in the milk to be 30-40%; Drying the powder is to quickly cool down the finished milk powder.

7. Infant formula milk powder with obesity prevention effect prepared by the preparation method according to any one of claims 1 to 6.

8. The infant formula milk powder with obesity prevention effect according to claim 7, characterized in that: Every 100 parts of formula milk powder contains: 17.72 parts of skimmed milk powder, 5.83 parts of desalted whey powder, 47.85 parts of lactose, 4.2 parts of MFGM / MPL, 23.88 parts of compound vegetable oil, 0.15 parts of compound vitamins, 0.2 parts of compound minerals, 0.15 parts of calcium chloride, and 0.02 parts of taurine.

9. The infant formula milk powder with obesity prevention effect according to claim 8, characterized in that: The mass ratio of each component of the complex vitamin is: Vitamin A 0.0005: Vitamin D 0.00009: Vitamin E 0.015: Vitamin C 0.13251: Vitamin B6 0.0016: Folic acid 0.0003; The mass ratio of each component of the composite mineral is: ferrous sulfate 0.013: zinc sulfate 0.005: magnesium sulfate 0.000022: calcium carbonate 0.181978; The mass proportion of each component of the composite vegetable oil is: rapeseed oil 10%, sunflower oil 10%, soybean oil 15%, coconut oil 25%, palm oil 25%, and corn oil 15%.

10. Use of the infant formula milk powder with obesity prevention effect according to any one of claims 7 to 9 in preparing food.

Images